Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 428 clinical trials
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may

epidermal growth factor
invasive cancer
monoclonal antibodies
absolute neutrophil count
step 2
  • 109 views
  • 23 Oct, 2022
  • 128 locations
Outpatient Treatment With Anti-Coronavirus Immunoglobulin (OTAC)

participants who receive neutralizing monoclonal antibodies (nMAbs) as standard of care (SOC), estimated to be about 20% of participants. Stratum 2 will be participants who do not receive nMAbs, estimated to

  • 0 views
  • 24 Apr, 2022
  • 34 locations
Immuno-Genetic, Inflammation, Retro-Virus, Environment (I-Give)

personalized psychiatry tailored to the needs of each patient. Notably, monoclonal antibodies anti-HERV-W Env will be assessed in a preclinical model for their ability to slow, stop, or even reverse the

Accepts healthy volunteers
schizophrenia
bipolar disorder
psychiatric disorder
psychosis
  • 52 views
  • 04 Oct, 2022
  • 5 locations
A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma

(paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted

  • 0 views
  • 21 Oct, 2022
  • 21 locations
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune

germ cell tumor of ovary
metastatic disease
ACTH
germ cell tumor
other cancer
  • 6651 views
  • 22 Oct, 2022
  • 752 locations
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

This multicenter, prospective, open-label, randomized, superiority phase 3 study is designed to demonstrate that treatment with a triple combination of acalabrutinib, obinutuzumab and venetoclax (GAVe) prolong the progression-free survival (PFS) as compared to treatment with the combination of obinutuzumab and venetoclax (GVe) in pa-tients with high risk CLL (defined as …

acalabrutinib
obinutuzumab
gilbert's syndrome
TP53
platelet count
  • 0 views
  • 27 May, 2022
  • 2 locations
A Phase 1/2 Study of Relatlimab (Anti-LAG-3 Monoclonal Antibody) Administered in Combination With Both Nivolumab (Anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1 Inhibitor) or in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

The purpose of this study is to demonstrate the safety and preliminary activity with triple combinations of relatlimab in combination with nivolumab and BMS-986205, or in combination with nivolumab and ipilimumab in immunotherapy-naive and pretreated populations across select advanced tumor types.

ipilimumab
measurable disease
  • 13 views
  • 17 Oct, 2022
  • 10 locations
MInimal Residual Disease Adapted Strategy (MIDAS)

IFM 2020-02 will enroll patients eligible for ASCT less than 66 years. All patients will receive induction based on 6 cycles (28-day) of KRD-Isatuximab (Isa-KRD), in order to achieve deep responses and high MRD negativity rates. Patients will be classified at diagnosis according to cytogenetics (standard vs high-risk cytogenetics defined …

neutrophil count
platelet count
anemia
measurable disease
erythropoietin
  • 0 views
  • 26 Apr, 2022
  • 51 locations
Safety and Efficacy of L9LS, a Human Monoclonal Antibody Against Plasmodium Falciparum, in an Age De-Escalation, Dose-Escalation Trial and a Randomized, Placebo-Controlled, Double-Blind Trial of Children in Western Kenya

The purpose of this study is to evaluate the safety and tolerability of one-time subcutaneous (SC) administration of monoclonal antibody (MAb) L9LS in healthy Kenyan children aged 5 months to 10 years, as well as the protective efficacy of one or two doses of L9LS against naturally occurring Plasmodium falciparum …

Accepts healthy volunteers
  • 0 views
  • 19 Oct, 2022
Dose Tapering and Early Discontinuation to InCreAse cosT-effectIveness Of Immunotherapy for NSCLC

Rationale: Immune checkpoint inhibitors have shown to improve the overall survival for patients with metastasized non-small cell lung carcinoma (NSCLC) but the optimal dosing and patient selection are still a matter of discussion. The pembrolizumab dose, for instance, may be reduced significantly without decreasing treatment efficacy. Furthermore, as approximately only …

carcinoma
cancer chemotherapy
lung carcinoma
pembrolizumab
  • 0 views
  • 25 Jul, 2021
  • 1 location